Gain Therapeutics, Inc. (GANX)
|Net Income (ttm)||n/a|
|Trading Day||May 14|
|Day's Range||9.11 - 9.97|
|52-Week Range||8.75 - 17.93|
Completed successful initial public offering and raised $46 million in gross proceeds --- Appointed four new independent board of directors to strengthen leadership team --- Signed a multi-target collab...
Gain Therapeutics Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds...
Compounds reverse the neurodegenerative process observed in a Parkinson's disease in vivo model
BETHESDA, Md., April 27, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric bi...
Gain Therapeutics Announces Presentation at the International Association of Parkinsonism and Related Disorders 2021 ...
Abstract highlighting Gain's STAR candidate for Parkinson's disease selected as one of the 10 Best Abstracts at the conference Abstract highlighting Gain's STAR candidate for Parkinson's disease selecte...
Gain Therapeutics Announces Multi-Target Drug Discovery Collaboration Agreement with Zentalis Pharmaceuticals
Collaboration to use Gain's proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) computational platform technology to identify new and previously difficult-to-drug oncology targets
Gain Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Overallotment Optio...
BETHESDA, Md., March 25, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced the closing of its initial public offering of 3,636,364 shares of its common stock and full exercise of...
Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...
Gain Therapeutics, Inc. (“Gain”) today announced the pricing of its initial public offering of...
Gain Therapeutics, Inc. (“Gain”) today announced that it has launched the roadshow for its initial...
Gain Therapeutics, a preclinical biotech developing small molecule therapies for lysosomal storage disorders, filed on Friday with the SEC to raise up to $40 million in an initial public offering.
Gain Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
Gain Therapeutics is a development stage biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (“LSDs”), including rare genetic diseases and neurological disorders. We use our exclusively in-licensed proprietary platform, Site-Directed Enzyme Enhancement Therapy (“SEE-Tx”), to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, potentially treatin... [Read more...]
|IPO Date |
Mar 18, 2021
Eric I. Richman
|Stock Exchange |
|Ticker Symbol |
In 2020, GANX's revenue was $28,881, a decrease of -30.07% compared to the previous year's $41,301. Losses were -$3.58 million, 63.1% more than in 2019.